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Abstract 
Purpose: The purpose of this study was to evaluate the capability of u-SPECT-II/CT to 
monitor the progression of breast cancer lung metastasis using 
99mTc-3P-RGD2 as a radio-
tracer.  
Methods: The breast cancer lung metastasis model was established by tail-vein injection of 2 
x 10
5 – 1.5 x 10
6 MDA-MB-231 cells into each athymic nude mouse. SPECT/CT studies were 
performed at a specified time after inoculation of MDA-MB-231 cells. Histological staining was 
used to further confirm the presence of lung metastases.  
Results: We found that both inoculation time and tumor cell load had significant influence on 
the extent of lung metastasis. For example, if animals were injected with 2 x 10
5 MDA-MB-231 
cells, there were no detectable metastatic breast tumors in the lungs after 8 weeks. If animals 
were injected with 1 x 10
6 MDA-MB-231 cells, there were many tumors in both lungs at week 
8. When 1.5 x 10
6 MDA-MB-231 cells were injected, the animal became very weak by week 7. 
We also found a rare example of breast cancer metastasis in the muscle and mediastinal lymph 
nodes. The tumor necrotic regions were clearly delineated by u-SPECT-II/CT.  
Conclusion: This study clearly demonstrated that 
99mTc-3P-RGD2 is an excellent radiotracer 
for noninvasive imaging of metastatic breast tumors in the lungs, mediastinal lymph nodes and 
muscles. 
99mTc-3P-RGD2 SPECT/CT is an outstanding platform for monitoring the progres-
sion of breast cancer lung metastases, semi-quantification of breast tumor load in the lungs 
and delineation of tumor necrosis in small animals. 
Key words: Breast Cancer Lung Metastasis; 99mTc-3P-RGD2; u-SPECT-II/CT. 
Introduction 
Breast cancer is the most commonly diagnosed 
cancer in women worldwide. Metastatic breast cancer 
is characterized by spreading cancer cells into nearby 
breast tissue, and other body parts (e.g. bone, lymph 
nodes, liver and lungs), and remains the main cause of 
death  of  breast  cancer  patients.  As  in  many  other 
metastatic  cancer  types,  specific  molecular  changes 
occurring within tumor cells and the tumor microen-
vironment contribute to the detachment of tumor cells 
from the primary tumor mass, invasion into the tumor 
stroma,  intravasation  into  nearby  blood  vessels  or 
lymphatics, survival in the blood stream, extravasa-
tion  into  and  colonization  of  the  target  organ,  and 
finally, metastatic outgrowth [1-3].  
Elucidation  of  molecular  mechanisms  underly-
ing breast cancer metastasis has gained tremendously 
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from  small  animal  models  [1].  The  lung  metastasis 
model is often established by the tail vein injection of 
breast cancer cells [4]. Although this model has been 
broadly used to evaluate new anticancer drugs [1], it 
is difficult to accurately monitor the therapy response. 
There are several noninvasive imaging modalities for 
monitoring therapy response in small animal metas-
tasis models. These include optical imaging with bi-
oluminescence  or  fluorescence  [4-6],  magnetic  reso-
nance  imaging  (MRI)  [7],  positron  emission  tomog-
raphy (PET) [8] and in vivo confocal analysis during 
tumor development in small animals [9]. MRI relies 
on anatomical changes during and after therapy while 
optical imaging methods have limitations in imaging 
small metastasis due to their low spatial resolution. 
18F-FDG has been used for cancer diagnosis, staging 
and therapy monitoring [10]; but glucose metabolism 
may not be an ideal biomarker for treatment response 
due to its limited sensitivity in detecting small pul-
monary metastatic lesions [11]. Therefore, it will be of 
great interest to develop an imaging tool to monitor 
the progression of breast cancer lung metastasis in a 
noninvasive fashion.  
Angiogenesis is one of the key requirements for 
tumor growth and metastasis [12-14], and is regulated 
by proteins, such as angiogenesis inhibitors and in-
tegrins.  Among  the  integrins  identified  and  charac-
terized  so  far,  integrin  v3  is  studied  most  exten-
sively. Integrin v3 is a receptor for extracellular ma-
trix  proteins  with  the  exposed  argi-
nine-glycine-aspartic (RGD) tripeptide sequence. It is 
expressed at low levels on epithelial cells and mature 
endothelial  cells,  but  is  highly  expressed  in  neuro-
blastomas,  glioblastomas,  melanomas,  and  carcino-
mas of the breast and lung [15-19]. The altered integ-
rin αvβ3 expression has been detected in breast cancer 
[20-22], and correlated with an aggressive phenotype 
and metastatic dissemination [21, 22]. It was reported 
that  integrin  αvβ3  is  over-expressed  on  both  tumor 
cells and activated endothelial cells on the neovascu-
lature of the breast cancer xenografts [23]. All these 
facts make integrin αvβ3 an interesting biomarker for 
noninvasive  diagnosis  of  breast  cancer  and  related 
metastasis by PET or SPECT (single photon emission 
computed tomography).  
Radiolabeled cyclic RGD peptides are radiotrac-
ers targeting the integrin αvβ3 expressed on both tu-
mor  cells  and  tumor  neovasculature  [24-27]. 
[18F]Galacto-RGD  and  [18F]AH111585  are  18F-labeled 
cyclic RGD peptides, and are currently under clinical 
trials for noninvasive detection of tumors and related 
metastasis by PET in cancer patients [28-30]. It was 
found  that  the  radiotracer  tumor  uptake  correlated 
well with the integrin αvβ3 expression levels. A sig-
nificant challenge for them to assume a wide-spread 
utility is their clinical availability at low cost. A phase 
I  study  was  reported  for  99mTc-NC100692,  a 
99mTc-labeled RGD peptide monomer [31]. Although 
clinical data showed that 99mTc-NC100692 was able to 
detect  malignant  lesions,  the  intensive  liver  uptake 
and hepatobiliary excretion will limit its continuing 
clinical  applications.  Therefore,  there  is  an  unmet 
medical need for more efficient radiotracers that are 
clinically  useful  for  early  detection  of  the  integrin 
αvβ3-positive tumors and their related metastasis.  
99mTc-3P-RGD2([99mTc(HYNIC-3P-RGD2)(tricine)
(TPPTS)]: HYNIC = 6-hydrazinonicotinyl; 3P-RGD2 = 
PEG4-E[PEG4-c(RGDfK)]2;  PEG4=  15-amino-4,7,10,13- 
tetraoxapentadecanoic acid; and  TPPTS = trisodium 
triphenylphosphine-3,3',3''-trisulfonate)  is  a  99mTc- 
labeled cyclic RGD peptide dimer. In animal models, 
99mTc-3P-RGD2 shows high tumor uptake, rapid renal 
clearance, and high metabolic stability [32, 33]. It is 
currently  under  clinical  investigations  as  a  SPECT 
radiotracer for imaging lung carcinomas [34]. Previ-
ously,  we  found  that  99mTc-3P-RGD2  was  useful  for 
detection of αvβ3-postive tumors in small animals [32, 
35], and its tumor uptake was correlated well to the 
integrin  αvβ3  expression  levels  [35].  Recently,  we 
found that 99mTc-3P-RGD2 SPECT/CT was useful for 
accurate quantification of the tumor radioactivity ac-
cumulation and delineation of necrotic regions [36]. 
The objective of this study was to evaluate the capa-
bility of  99mTc-3P-RGD2 SPECT/CT as a noninvasive 
imaging  tool  to  monitor  the  progression  of  breast 
cancer lung metastasis.  
 Materials and Methods 
Materials  and  Analytical  Method.  Trisodium 
triphenylphosphine-3,3',3''-trisulfonate  (TPPTS)  and 
tricine were purchased from Sigma/Aldrich (St. Lou-
is,  Missouri).  HYNIC-3P-RGD2  (HYNIC  = 
6-(2-(2-sulfonato-benzaldehyde)hydrazono)nicotinyl; 
3P-RGD2  =  PEG4-E[PEG4-c(RGDfK)]2),  and  PEG4  = 
15-amino-4,7,10,13-tetraoxapentadecanoic  acid)  was 
prepared using the literature method [32]. Na99mTcO4 
was obtained from Cardinal HealthCare (Chicago, IL). 
The radio-HPLC method used a LabAlliance system 
equipped with a -ram IN-US detector and Zorbax C18 
column (4.6 mm x 250 mm, 300 Å pore size). The flow 
rate was 1 mL/min. The mobile phase was isocratic 
with 90% solvent A (25 mM NH4OAc buffer, pH = 5.0) 
and 10% solvent B (acetonitrile) at 0 – 5 min, followed 
by a gradient mobile phase from 10% B at 5 min to 
40% B at 20 min.  
Radiolabeling  and  Dose  Preparation. 
99mTc-3P-RGD2 was prepared according to literature 
method [32] using lyophilized kit formulation, which Theranostics 2012, 2(6) 
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contains 20 μg HYNIC-3P-RGD2, 5 mg TPPTS, 6.5 mg 
tricine, 40 mg mannitol, 38.5 mg disodium succinate 
hexahydrate and 12.7 mg succinic acid. 99mTc-labeling 
was accomplished by adding 1 – 1.5 mL of Na99mTcO4 
solution (1,110  – 1,850 MBq). The reconstituted vial 
was heated at 100 °C for 30 min. The resulting solu-
tion was analyzed by radio-HPLC. The radiochemical 
purity  (Supplementary  Material:  Figure  SI1)  was 
>95% for all imaging studies. Doses were prepared by 
dissolving the radiotracer in saline to a concentration 
of 370 – 555 MBq/mL. Each animal was injected with 
~0.1 mL (37 – 55 MBq/1.25 – 1.5 g HYNIC-3P-RGD2) 
of the dose solution. 
Animal Model. Animal studies were carried out 
in  compliance  with  the  NIH  animal  experiment 
guidelines  (Principles of Laboratory Animal Care,  NIH 
Publication no. 86-23, revised 1985). The animal pro-
tocol was approved by the Purdue University Animal 
Care and Use Committee (PACUC No. 04-014-2010). 
MDA-MB-231  cell  line  was  obtained  from  ATCC 
(Manassas,  VA).  The  MDA-MB-231  cells  were  cul-
tured in the RPMI Medium 1640 supplemented with 
10% fetal bovine serum (FBS, ATCC) and 1% penicil-
lin and streptomycin (GIBCO) solution at 37 °C in a 
humidified  atmosphere  of  5%  CO2  in  air.  Female 
athymic nu/nu mice at 4 – 5 weeks of age were pur-
chased from Harlan (Indianapolis, IN). The lung me-
tastasis  model  was  established  by  injecting 
MDA-MB-231 cells into the tail vein of each animal. 
SPECT/CT studies were performed at the specified 
time after inoculation of tumor cells.  
u-SPECT/CT. SPECT/CT images were obtained 
using a u-SPECT-II/CT scanner (Milabs, Utrecht, The 
Netherlands) equipped with a 0.6 mm multi-pinhole 
collimator.  The  tumor-bearing  mouse  was  injected 
with 37 – 55.5 MBq of 99mTc-3P-RGD2 via the tail-vein. 
At 60 min post-injection (p.i.), the animal was placed 
into  a  shielded  chamber  connected  to  an  isoflurane 
anesthesia unit (Univentor, Zejtun, Malta). Anesthesia 
was induced using an air flow rate of 350 mL/min 
and ~3.0% isoflurane. After induction of anesthesia, 
the  animal  was  immediately  placed  supine  on  the 
scanning bed. The air flow rate was reduced to ~250 
mL/min with ~2.0% isoflurane. Rectangular scan in 
regions of interest (ROIs) from both the SPECT and 
CT were selected based on orthogonal optical images 
provided  by  integrated  webcams.  After  SPECT  ac-
quisition  (75  projections  over  30  min  per  frame,  2 
frames), the animal was then translated into the at-
tached CT and imaged using the „normal‟ acquisition 
settings (2 degree intervals) at 45 kV and 500 A. After 
imaging,  the  animal  was  allowed  to  recover  in  a 
lead-shielded cage.  
Image  Reconstruction  and  Data  Processing. 
SPECT reconstruction was performed using a POSEM 
(pixelated ordered subsets by expectation maximiza-
tion) algorithm with 6 iterations and 16 subsets. CT 
data  were  reconstructed  using  a  cone-beam  filtered 
back-projection  algorithm  (NRecon  v1.6.3,  Skyscan). 
After  reconstruction,  the  SPECT  and  CT  data  were 
automatically  co-registered  according  to  the  move-
ment of robotic stage, and re-sampled to equivalent 
voxel  sizes.  Co-registered  images  were  further  ren-
dered  and  visualized  using  the  PMOD  software 
(PMOD  Technologies,  Zurich,  Switzerland).  A 
3D-Guassian filter (0.8 mm FWHM) was applied to 
smooth  noise,  and  LUTs  (look-up  tables)  were  ad-
justed for good visual contrast. Reconstructed images 
were visualized as both orthogonal slices and maxi-
mum intensity projections.  
Radioactivity Quantification. Radiation sources 
of known amount of radioactivity were imaged and 
reconstructed using the same scanning protocol de-
scribed  above.  A  standard  curve  (Supplementary 
Material:  Figure SI2) was generated to correlate the 
pixel intensities in reconstructed images to the radio-
activity measured by the -counter (Shelton, CT). The 
organ delineation was performed on SPECT/CT im-
ages. ROIs were drawn manually to cover entire or-
gan in the transverse view of SPECT/CT image. The 
organ volume and radioactivity counts  were gener-
ated using the PMOD software. The radioactivity in 
each  organ  was  calculated  according  to  the  above 
mentioned standard curve (Supplementary Material: 
Figure SI2). The organ uptake was expressed as the 
percentage of injected dose (%ID) and percentage of 
injected dose per unit volume (%ID/cm3). For tumor 
necrosis quantification, the total tumor volume was 
determined by CT, and the volume of viable tumor 
was  measured  by  SPECT.  The  difference  between 
these  two  values  represents  the  volume  of  necrotic 
tumor tissues. The percentage of tumor necrosis was 
calculated using the following equation: % necrosis = 
100  x  (the  volume  of  necrotic  tissue)/(total  tumor 
volume). The tumor/necrosis (T/N) ratios were cal-
culated by circling an area (~0.01cm3) of necrotic re-
gion with the lowest radioactivity accumulation and 
an equally sized area of viable tumor with high radi-
oactivity accumulation.  
Hematoxylin  and  Eosin  (H&E)  Staining.  All 
tissues of interest harvested from the tumor-bearing 
mice  two  days  after  SPECT/CT  were  fixed  in  10% 
formalin.  Bone  tissues  were  decalcified  with  eth-
ylenediaminetetraacetic  acid  (EDTA)  until  they  be-
came soft. Tissues were embedded in paraffin. The 4 
m  sections  were  de-paraffinized  and  re-hydrated. 
Tissue  sections  were  stained  with  hematoxylin  and 
eosin  to  study  the  morphology  under  microscope. Theranostics 2012, 2(6) 
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Aperio's ImageScope Viewer (Vista, CA) was used to 
visualize the whole-slide scans and capture images. 
Immunohistochemistry.  Tumors  were  embed-
ded  in  the  OCT  (optimal  cutting  temperature  com-
pound)  solution  immediately  after  removal, 
snap-frozen in liquid nitrogen, and then cut into 5 μm 
slices. After drying thoroughly at room temperature, 
the slides were fixed with ice-cold acetone for 10 min, 
and  dried  in  the  air  for  20  min.  The  sections  were 
blocked  with  10%  goat  serum  for  30  min  at  room 
temperature,  and  were  incubated  with  the  hamster 
anti-integrin β3 antibody (1:100, BD Biosciences, San 
Jose, CA) and rat anti-CD31 antibody (1:100, BD Bio-
sciences) for 1 h at room temperature. After incubat-
ing  with  the  Cy3-conjugated  goat  anti-hamster  and 
fluorescein (FITC)-conjugated goat anti-rat secondary 
antibodies (1:100, Jackson ImmunoResearch Inc., West 
Grove, PA) and washing with PBS, the fluorescence 
was  visualized  with  an  Olympic  BX51  fluorescence 
microscope  (Olympus  America  Inc.,  Center  Valley, 
PA). Quantitative analysis of the integrin 3 expres-
sion was performed after immunostaining of tumor 
tissues. All images were obtained under 100x magni-
fication with the same exposure time. Brightness and 
contrast  adjustments  were  made  equally  to  all  the 
images. The average area of positively stained 3 on 
cryostat sections from at least 15 randomly selected 
fields in each slide was calculated to assess the rela-
tive expression in the tumor tissues by the NIH ImageJ 
software.  The  relative  3  level  was  expressed  as  a 
percentage (%) of the total area, and the ratio of the 
integrin expression in viable region to necrotic region 
was calculated.  
Statistical Analysis. All data were expressed as 
the means ± the standard deviation. Statistical analy-
sis  was performed by  one-way analysis  of variance 
(ANOVA)  followed  by  the  Newman-Keuls  test  for 
multiple comparisons. The level of significance was 
set at p < 0.05.  
Results  
Monitoring Progression of Breast Cancer Lung 
Metastasis.  Figure  1  shows  the  3D  and  transverse 
views of SPECT/CT images of athymic nude mice (n 
= 8) with breast cancer lung metastasis. These images 
were obtained at week 4, 6 and 8 after tail-vein injec-
tion of 1.0 x 106 MDA-MB-231 cells to determine how 
long it takes to develop the measurable lung metas-
tases in athymic nude mice. We found no metastatic 
breast tumor lesions detectable by u-SPECT/CT in the 
lungs  at  week  4  (Figure  1:  top).  By  week  6,  small 
breast cancer lesions started to appear in the medias-
tinum and lungs. At week 8, SPECT/CT images re-
vealed many metastatic cancer lesions in both lungs 
while the tumor in mediastinal lymph nodes became 
larger.  Histological  data  confirmed  the  presence  of 
these metastatic lesions in the lungs and mediastinum 
(Figure  1:  bottom),  and  were  completely  consistent 
with the results from SPECT/CT.  
Figure 2 compares the %ID (left) and %ID/cm3 
(right) uptake values of  99mTc-3P-RGD2 in the lungs. 
The tumor uptake values were calculated on the basis 
of SPECT/CT quantification in athymic nude mice (n 
= 8) at week 4, 6 and 8 after inoculation of 1.0 x 106 
MDA-MB-231  cells.  For  comparison  purposes,  the 
animals (n = 4) without lung metastasis were used in 
the  control  group.  Even  though  the  lung  uptake  of 
99mTc-3P-RGD2 (0.41 ± 0.05 %ID) at week 4 seemed to 
be higher than that in the control animals (0.36 ± 0.06 
%ID),  this  difference  was  not  significant  (p  >  0.05) 
within the experimental errors. At week 6, the tumor 
burden in the lungs became significant. The lung up-
take of  99mTc-3P-RGD2 was much higher (0.89 ± 0.12 
%ID; p < 0.01) than that in the control group. By week 
8, the uptake of  99mTc-3P-RGD2 in the lungs was in-
creased to 1.40 ± 0.42 %ID. In all cases, the lung size 
remained relatively unchanged (1.21 – 1.32 cm3) dur-
ing the 8-week study period.  
Tumor  Cell  Load  on  Progression  of  Breast 
Cancer Lung Metastasis. We examined the impact of 
tumor cell  load on the extent of breast cancer lung 
metastasis  by  injecting  different  number  of 
MDA-MB-231 cells. Figure 3 shows the 3D views of 
representative  SPECT/CT  images  of  the  athymic 
nude mice after tail vein injection of 2 x 105 (A: n = 4), 
1  x  106  (B:  n  =  8)  and  1.5  x  106  (C:  n  =  4)  of 
MDA-MB-231 cells. Obviously, the number of injected 
tumor cells had a significant impact on the extent of 
lung metastasis, which was consistent with the %ID 
(D)  and  %ID/cm3  (E)  lung  uptake  values  of 
99mTc-3P-RGD2.  For  example,  the  animals  injected 
with 2 x 105 of MDA-MB-231 cells showed no meta-
static  breast  cancer  lesions  detectable  by 
u-SPECT-II/CT in the lungs, lymph nodes and mus-
cles  8  weeks  after  tumor  cell  inoculation.  The  lung 
uptake  of  99mTc-3P-RGD2  was  0.40  ±  0.05  %ID  as 
compared to 0.37 ± 0.05 %ID in the normal animals. 
However,  histological  data  revealed  many  breast 
cancer  micrometastases  (Figure  3F),  which  were 
avascular and comprised of only several breast cancer 
cells.  They  are  likely  too  small  to  be  detected  by 
u-SPECT-II/CT (detection limit: ~1 mm in diameter 
[36]). In contrast, the animals administered with 1 x 
106 of MDA-MB-231 cells had many metastatic lesions 
in the lungs (Figure 3B) at week 8. The presence of 
metastatic breast cancer lesions was further confirmed 
by histological data (Figure 3G) of lung tissues and 
the increased lung uptake of  99mTc-3P-RGD2 (Figure Theranostics 2012, 2(6) 
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3D: 1.45 ± 0.45 %ID). When animals were adminis-
tered with 1.5 x 106 of MDA-MB-231 cells, SPECT/CT 
imaging had to be performed at week 7 since it be-
came  very  weak  due  to  the  reduced  lung  function. 
SPECT/CT images showed massive metastatic tumor 
lesions in lungs (Figure 3C), and the lung uptake of 
99mTc-3P-RGD2 was increased to 1.91 ± 0.68 %ID (Fig-
ure 3D). Histological data were completely consistent 
with the presence of massive metastatic breast tumors 
(Figure 3H).  
 
Figure 1. The 3D and transverse views of SPECT/CT images of an athymic nude mouse at week 4, 6 and 8 after tail-vein injection of 1.0 
x 106 MDA-MB-231 cells, along with the H&E stained slices (magnification: 15×) of the lung and mediastinal tissues. Only one animal 
showed the presence of mediastinal tumors, as indicated by yellow arrows.  
 
Figure 2. The %ID (left) and %ID/cm3 (right) uptake values of 99mTc-3P-RGD2 in the lungs obtained from SPECT/CT quantification in 
athymic nude mice (n = 8) at week 4, 6 and 8 after tail-vein injection of 1.0 x 106 MDA-MB-231 cells. Normal animals (n = 4) were used 
in the control group. †: p < 0.05, significantly different from the control group; *: p > 0.05, no significant difference from the control group.  Theranostics 2012, 2(6) 
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Figure 3. Top: The 3D SPECT/CT images for athymic nude mice after the tail-vein injection of 2 x 105 (A: n = 4 at week 8), 1 x 106 (B: 
n = 8 at week 8) and 1.5 x 106 (C: n = 4 at week 7) MDA-MB-231 breast cancer cells. Middle: The %ID (D) and %ID/cm3 (E) tumor uptake 
values of 99mTc-3P-RGD2 in the lungs obtained from SPECT/CT quantification. †: p < 0.01, significantly different from the group admin-
istered with 2 x 105 cells. Bottom: Representative H&E stained slices of lung tissues from animals injected with 2 x 105 (F: magnification 
= 200×), 1 x 106 (G: magnification = 200×) and 1.5 x 106 (H: magnification = 15×) cells. Arrows indicate the presence of metastatic breast 
tumors. 
 
Breast Cancer Metastasis in Muscle and Bone. 
It  is  well-accepted  that  tail-vein  injection  of  breast 
cancer  cells  leads  to  metastasis  in  lungs  while  in-
tra-cardiac  (left  ventricle)  injection  of  breast  cancer 
cells  often  result  in  formation  of  metastases  in  the 
bone, brain and liver [1, 2, 37]. However, we found 
that the tail-vein injection of MDA-MB-231 cells could 
also result in breast cancer metastases in the muscle. 
Figure 4A illustrates the 3D views of SPECT/CT im-
ages of an athymic nude mouse at week 4, 6 and 12 
after tail-vein injection of MDA-MB-231 cells. These 
images  were  obtained  to  show  the  progression  of 
metastatic tumors over 12 weeks. Figure 4B exhibits 
the coronal and sagittal views of the SPECT/CT im-
ages obtained at week 12 to illustrate the relative lo-
cation and characteristics of five different breast tu-
mors (designated as #1 – #5). As expected, no meta-
static breast cancer lesions were detectable at week 4. 
By week 6, there were several small metastatic breast 
tumors in the neck (#1), shoulder (#2), underarm (#3), 
back (#4) and hindlimb (#5). Since they were not seen 
in the SPECT/CT images of the same animal at week 
4, we believe that they are true “hot spots” due to the 
αvβ3 binding of 99mTc-3P-RGD2. At week 12, the small Theranostics 2012, 2(6) 
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breast  cancer  metastases  became  sizeable  solid  tu-
mors. It was surprising that no breast cancer lesions 
were detectable by u-SPECT-II/CT in the lungs. The 
radioactivity accumulation in tumors #1 and #2 was 
relatively  homogeneous  (Figure  4B:  coronal).  The 
distribution  of  99mTc-3P-RGD2  in  tumor  #3  was  do-
nut-shaped  (not  shell-shaped)  with  a  large  necrotic 
core (Figure 3B: sagittal). Tumor #4 is the largest (~1.2 
g) among 5 metastatic breast tumors in this animal, 
but it had the least uptake of 99mTc-3P-RGD2 with the 
radioactivity accumulating only in a small portion of 
its outside edge (Figure 4B: sagittal) due to extensive 
necrosis. The metastatic lesion #5 was clearly seen in 
the muscle of left hindlimb (Figure 4B: sagittal). The 
volume of necrotic tissue was calculated by subtract-
ing  the  volume  of  viable  tumor  (determined  by 
SPECT) from the total tumor volume (measured by 
CT). The percentage of tumor necrosis was estimated 
to be 44, 40, 55 and 94 for tumors #1, #2, #3 and #4, 
respectively. The majority of tumor #4 was necrotic 
with  little  radioactivity  accumulation.  Their  maxi-
mum tumor/necrosis (T/N) ratios were calculated to 
be 5.8, 6.3, 4.0 and 1.15, respectively. Because of the 
heterogeneity of tumor necrosis, these values should 
be used with caution.  
Figure  5  shows  histological  and  immunohisto-
chemical data for the selected metastatic breast tumor 
tissues. Tumors #1 and #2 were small (<0.4 cm3) with 
~40% necrosis (Figure 5A). As a result, the integrin 
v3  expression  was  relatively  homogeneous  in  the 
tumor tissue (Figure 5B). The ratio of the integrin v3 
expression in the viable tissue to that in the necrotic 
region was ~6:1, which is close to that obtained from 
SPECT/CT (Figure 4). Tumor #3 had more necrosis 
(~55%), and integrin v3 was expressed only on the 
outside edge of tumor tissue (Figure 5C). The integrin 
v3 level in the viable region (Figure 5D) was similar 
to that in tumors #1 and #2 (Figure 4B). Likewise, the 
vasculature, as stained in CD31 (green), was rich in 
the viable region, which was similar to small tumors 
(Figure 5: B vs. D). Tumor #4 was also highly necrotic 
with little viable tumor tissue (Figure 5E). Immuno-
histochemical data also indicated that there was no 
CD31  and  v3  expression  in  the  necrotic  regions 
(Figure 5F), which is completely consistent with the 
low uptake of 99mTc-3P-RGD2 in tumor #4 (Figure 5B). 
Tumor #5 was in the muscle (Figure 5G) instead of 
bone. The breast tumor cells have already penetrated 
into  the  joint-bone  and  caused  significant 
bone-resorption (Figure 5H).  
Discussion  
In this study, we found that u-SPECT-II/CT is a 
very  useful  tool  to  study  the  progression  of  breast 
cancer  lung  metastases.  The  resolution  of 
u-SPECT-II/CT  (<  0.5  mm)  is  higher  than  that  ob-
tained  with  bioluminescence  and  fluorescence  [4-6]. 
We also found that 99mTc-3P-RGD2 SPECT/CT has the 
capability to quantify or semi-quantify the metastatic 
breast  tumor  load  in  the  lungs  (Figures  2  and  3), 
which is consistent with the results obtained from the 
glioma-bearing  animal  model  [36].  These  findings 
may  have  several  important  implications  in  both 
clinical practice and basic cancer research using small 
animal  models.  For  example,  99mTc-3P-RGD2 
SPECT/CT could be used as a screening tool to select 
appropriate cancer patients who would benefit most 
from anti-αvβ3 therapy. If the tumor in a patient has a 
high integrin αvβ3 expression anti-αvβ3 therapy would 
more likely be effective. If the tumor has little integrin 
αvβ3 expression, anti-αvβ3 therapy would not be effec-
tive regardless  of the  amount  of anti-αvβ3 drug ad-
ministered  into  patients.  Another  potential  applica-
tion  is  the  utility  of  99mTc-3P-RGD2  SPECT/CT  for 
monitoring  antiangiogenic  therapy  in  small  animal 
lung  metastasis  models  by  determining  the  tumor 
burden in lungs during and after treatment. If antian-
giogenic therapy is effective, there would be a signif-
icantly reduced tumor burden in the lungs. As a re-
sult,  the  lung  uptake  of  99mTc-3P-RGD2  would  be 
lower than that under the baseline conditions before 
therapy. If the antiangiogenic therapy is not effective, 
the tumor burden would be increased in the lungs. In 
this  situation,  the  lung  uptake  of  99mTc-3P-RGD2 
would be higher than that before therapy.  
Two important factors (the inoculation time and 
the total number of breast tumor cells) have signifi-
cant influence on the extent of metastasis in athymic 
nude mice. In general, more tumor cells injected into 
each animal will lead to the faster formation of more 
breast cancer lung metastases. If the animal is injected 
with 2 x 105 MDA-MB-231 cells, there are no detecta-
ble metastatic breast tumors in the lungs even 8 weeks 
after cell inoculation (Figure 3A) with the radioactiv-
ity  accumulation  comparable  to  that  in  the  normal 
animals (Figure 3: D and E). When the animal is in-
jected with 1 x 106 MDA-MB-231 cells, there are many 
metastatic breast tumor lesions at week 8 (Figure 3B) 
and  the  lung  uptake  of  99mTc-3P-RGD2  was  signifi-
cantly increased (Figure 3: D and E). If each animal is 
injected with 1.5 x 106 MDA-MB-231 cells, the animal 
becomes  very  weak  by  week  7  due  to  the  reduced 
lung  function  caused  by  massive  lung  metastasis 
(Figure 3: C and H). As a result, the tumor load in the 
lungs was highest among three groups (Figure 3: D 
and E).  
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Figure 4. A: The 3D views of SPECT/CT images of an athymic nude mouse obtained at week 4, 6 and 12 after tail-vein injection of 1.0 x 
106 MDA-MB-231 cells. B: Coronal and sagittal views of SPECT/CT images obtained at week 12 after tumor cell inoculation to illustrate 
the location of metastatic breast tumors in the neck (#1), back (#2 and #4), underarm (#3) and thigh (#5). *The tumor/necrosis ratio was 
calculated by circling an area (~0.01cm3) of necrotic region with the lowest radioactivity accumulation and an equally sized area of viable 
tumor with high radioactivity accumulation. **The percentage of tumor necrosis was estimated on the basis of total tumor volume 
determined by CT and the volume of viable tumor measured by SPECT.  
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Figure 5: A: Selected H&E staining data representing the metastatic breast tumors (#1 and #2) with ~40% necrosis. B: Representative 
overlay image of tumor slice stained with anti-integrin 3 (red color) or anti-CD31 (green color) antibody. Yellow color (red integrin β3 
staining merged with green CD31 staining) indicates the presence of integrin v3 on tumor neovasculature. C: Selected H&E staining data 
for tumor #3 (only half of the whole tumor tissue). D: The overlay image of tumor slice in the viable region stained with anti-integrin 3 
(red) or anti-CD31 (green) antibody. E: H&E staining data for tumor #4 with extensive necrosis and little viable tumor tissue on the upper 
right edge. F: The overlay image of tumor slice in the necrotic tumor tissue stained with anti-integrin 3 (red) or anti-CD31 (green) 
antibody. G: Selected H&E staining data for tumor #5 in the left limb. H: Expanded region between two joint-bones. The tumor cells have 
penetrated into the joint-bone, but the tumor tissue remains largely in the muscle instead of inside the bone. 
 
 It is important to note that the lack of metastatic 
lung lesions in the SPECT/CT images does not nec-
essarily  always  mean  “no  metastasis”.  In  experi-
mental models of metastasis, it is not uncommon to 
find that there are no visible metastases in the lungs, 
but  histological  data  reveals  micrometastases  con-Theranostics 2012, 2(6) 
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sisting of many small tumor colonies [37]. As illus-
trated  in  Figure  3F,  there  are  indeed  many  breast 
cancer  lung  micrometastases.  Therefore,  histological 
analysis must be used to further confirm the results 
obtained from the SPECT/CT studies. It is also im-
portant to emphasize that the occurrence of metastasis 
in the bone, mediastinum and muscle is not common 
if MDA-MB-231 breast cancer cells are injected via the 
tail-vein. In this study, only one animal (1 out of 17 
animals) had metastatic breast cancer lesions in me-
diastinum and one animal (1 out of 17 animals) had 
intramuscular and bone metastases. The remaining 15 
animals all developed breast cancer lung metastases 
under the conditions used in this study.  
MDA-MB-231  human  breast  cancer  cells  have 
high expression of integrin v3 (Supplementary Ma-
terial: Figure SI3), which strongly promotes metastasis 
by enhancing interactions between circulating tumor 
cells and platelets and promoting tumor cell arrest in 
the vasculature [38]. The integrin v3 also supports 
the  tumor  cell  interaction  with  platelets  and  leuko-
cytes  during  blood  flow,  which  results  in  shear  re-
sistant, and tumor cell arrest [38]. The integrin v3 
expression  on  circulating  tumor  cells  in  a  constitu-
tively activated functional form or in a state that al-
lows  rapid  activation  under  blood  flow  conditions 
provides  advantages  for  breast  cancer  metastasis. 
When  MDA-MB-231  cells  are  injected  from  the  tail 
vein, they are often trapped in pulmonary capillaries. 
Small intrapulmonary nodules are formed as “tumor 
cell clusters” or micrometastases, which may subse-
quently spread into mediastinal lymph nodes. Thus, it 
is not unexpected that small breast cancer lesions are 
detected in the mediastinum by u-SPECT/CT (Figure 
1) at week 6.  
Breast cancer has a propensity to metastasize to 
bone, lymph nodes, lung, liver, and (rarely) adrenal 
glands [1, 2]. In this study, we showed a rare case of 
muscle  metastasis  (Figure  4A),  as  indicated  by  the 
presence of many muscle cells within tumors #1 and 
#2  (Figure  4A).  It  is  interesting  to  note  that  intra-
muscular breast cancer metastasis is rarely reported in 
preclinical  tumor-bearing  animal  models.  Although 
the exact mechanism is not clear, it is possible that the 
injected  breast  tumor  cells  cross  the  lungs  without 
staying, and enter the left atrium. Tumor cells then 
circulate in the blood stream, and are finally trapped 
in  intramuscular  microvessels.  These  breast  tumor 
cells  may  eventually  develop  into  measurable  solid 
tumors in the muscle.  
Tumor necrosis is caused by rapid tumor growth 
and slow angiogenesis. Deficient blood supply results 
in tumor cell death and tissue necrosis [39]. It has been 
found that the breast tumors with necrosis were asso-
ciated with their poor prognosis [40]. Imaging spon-
taneous necrosis in tumor tissues and the tumor ne-
crosis developed after chemotherapy, radiation ther-
apy or combination thereof have significant impact on 
the management of cancer patients [41]. In this study, 
we show that 99mTc-3P-RGD2 SPECT/CT is useful to 
identify  the  integrin  αvβ3-negative  necrotic  regions. 
The pattern of necrosis can be different substantially 
among the tumors from the same animal (Figure 4: C 
and E). For example, the radioactivity distribution in 
tumor #3 is donut-shaped with a large necrotic core 
(Figure  4B)  while  the  radioactivity  in  tumor  #4  ac-
cumulates only in a small portion of its outside edge 
because of extensive necrosis. It must be noted that 
quantification of tumor necrosis is not an easy task. 
There are many necrotic regions in each tumor even if 
it is from the same animal. Each tumor slice in the 
SPECT/CT image is different and each area in that 
specific slice is also different with respect to the radi-
otracer  tumor  uptake  and  integrin  αvβ3  expression 
levels. Thus, the % tumor necrosis and maximal T/N 
ratios were estimated to illustrate the relative radio-
activity accumulation in tumors with necrosis. 
Conclusion 
In this study, we found that the tail-vein injec-
tion  of  MDA-MB-231  cells  into  each  athymic  nude 
mouse will generally lead to lung metastasis; but it 
may also result in metastasis in the mediastinal lymph 
nodes and muscles. It takes 6 – 8 weeks to develop 
metastatic lesions (≥1 mm) in the lungs if the animal is 
injected with 1 x 106 MDA-MB-231 cells. We clearly 
demonstrate that 99mTc-3P-RGD2 is an excellent radi-
otracer for noninvasive imaging of metastatic breast 
tumors  in  the  lungs,  mediastinal  lymph  nodes  and 
muscles. 99mTc-3P-RGD2 SPECT/CT is an outstanding 
platform  for  monitoring  the  progression  of  breast 
cancer  lung  metastases,  semi-quantification  of  the 
metastatic tumor burden in the lungs and delineation 
of  tumor  necrosis  in  small  animals.  99mTc-3P-RGD2 
SPECT/CT may have clinical applications for nonin-
vasive  monitoring of the response to chemotherapy 
and/or radiotherapy.  
Supplementary Material 
Fig.SI1 - Fig.SI3. 
http://www.thno.org/v02p0577s1.pdf 
Acknowledgements 
Authors would thank Dr. Aaron B. Taylor for his 
technical assistance in SPECT/CT studies, and Purdue 
University  for  the  purchase  of  the  u-SPECT-II/CT 
scanner  (Milabs, Utrecht, The Netherlands). This  work 
was  supported  by  Purdue  University  and  research Theranostics 2012, 2(6) 
 
http://www.thno.org 
587 
grants: R01 CA115883 (S.L.) from the National Cancer 
Institute (NCI) and KG111333 (Y.Z. and S.L.) from the 
Susan G. Komen Breast Cancer Foundation. 
Abbreviation 
CT:  computer  tomography;  EDTA:  ethylenedi-
aminetetraacetic acid; FBS: fetal bovine serum; FDG: 
2-deoxy-2-fluoro-D-glucose;  [18F]Galacto-RGD: 
2-[18F]fluoropropanamide  c(RGDfK(SAA);    SAA: 
7-amino-L-glyero-L-galacto-2,6-anhydro-7-deoxyhept
anamide; FITC: fluorescein;  H&E: hematoxylin and 
eosin;    HPLC:  high  performance  liquid  chromatog-
raphy; LUT: look-up table; MRI: magnetic resonance 
imaging;    PET:  positron  emission  tomography;  
POSEM:  pixelated  ordered  subsets  by  expectation 
maximization;  RCP:  radiochemical  purity;  RGD:  ar-
ginine-glycine-aspartic;  ROI:  region  of  interest;  
SPECT:  single  photon  emission  computed  tomogra-
phy. 
Competing Interests 
The  authors  have  declared  that  no  competing 
interest exists. 
References 
1.  Fantozzi A, Christofori G. Mouse models of breast cancer metasta-
sis. Breast Cancer Res 2006; 8: 212-222.  
2.  Kim IS, Baek SH. Mouse models for breast cancer metastasis. Bio-
chem Biophys Res Commun 2010; 394: 443–447.  
3.  Chambers  AF,  Groom  AC,  MacDonald  IC.  Dissemination  and 
growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 
563–572.  
4.  Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, 
Olshen  AB,  Gerald  WL,  Massagué  J.  Genes  that  mediate  breast 
cancer metastasis to lung. Nature 2005; 436: 518–524.  
5.  Kaijzel EL, van der Pluijm G, Löwik CW. Whole-body optical im-
aging in animal models to assess cancer development and progres-
sion. Clin Cancer Res 2007; 13: 3490–3497. 
6.  Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, 
Ponomarev  V,  Gerald  WL,  Blasberg  R,  Massagué  J.  Distinct  or-
gan-specific  metastatic  potential  of  individual  breast  cancer  cells 
and primary tumors. J Clin Invest 2005; 115: 44–55. 
7.  Zhao D,  Richer  E,  Antich  PP, Mason  RP.  Antivascular  effects  of 
combretastatin A4 phosphate in breast cancer xenograft assessed 
using dynamic bioluminescence imaging and confirmed by MRI. 
FASEB J 2008, 22: 2445–2451.  
8.  Kramer-Marek  G,  Kiesewetter  DO,  Capala  J.  Changes  in  HER2 
expression in breast cancer xenografts after therapy can be quanti-
fied using PET and 18F-labeled affibody molecules. J Nucl Med 2009; 
50: 1131–1139.  
9.  Gonda  K,  Watanabe  TM,  Ohuchi  N,  Higuchi  H.  In  vivo 
nano-imaging of membrane dynamics in metastatic tumor cells us-
ing quantum dots. J Biol Chem 2010; 285: 2750–2757.  
10.  Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in 
the diagnosis and management of patients with breast cancer: part 
2-response  to  therapy,  other  indications,  and  future  directions.  J 
Nucl Med 2009; 50: 738–748.  
11.  Bestic JM, Peterson JJ, Bancroft LW. Use of FDG PET in staging, 
restaging, and assessment of therapy response in Ewing sarcoma. 
RadioGraphics 2009; 29: 1487–1501.  
12.  Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integ-
rin v3 for angiogenesis. Science 1994; 264: 569–571. 
13.  Desgrosellier JS, Cheresh DA. Integrins in cancer: biological impli-
cations  and  therapeutic  opportunities.  Nat  Rev  Cancer 2010;  10: 
9–22. 
14.  Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri 
ZM,  Ginsberg MH,  Hughes  PE,  Pampori  N,  Shattil  SJ,  Saven  A, 
Mueller BM. Integrin activation controls metastasis in human breast 
cancer. Proc Natl Acad Sci USA 2001; 98: 1853–1858. 
15.  Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, 
Strasser JF, Villani R, Cheresh DA, Black PM. v3 and v5 integrin 
expression in glioma periphery. Neurosurgery 2001; 49: 380–389.  
16.  Smythe WR, LeBel E, Bavaria JE, Kaiser LR, Albelda SM. Integrin 
expression in non-small cell carcinoma of the lung. Cancer Metas-
tasis Rev 1995; 14: 229–239. 
17.  Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angio-
genesis  correlates  with  metastatic  disease,  N-myc-amplification, 
and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 
405–414.  
18.  Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, 
Di Filippo F, Giannarelli D, Temponi M, Ferrone S. Clinical signifi-
cance  of  v3  integrin  and  intercellular  adhesion  molecule-1  ex-
pression  in  cutaneous  malignant  melanoma  lesions.  Cancer  Res 
1997; 57: 1554–1560.  
19.  Sengupta S, Chattopadhyay N, Mitra A, Ray S, Dasgupta S, Chat-
terjee A. Role of v3 integrin receptors in breast tumor. J Exp Clin 
Cancer Res 2001; 20: 585–590.  
20.  Havaki S, Kouloukoussa M, Amawi K, osos Y, Arvanitis LD, Goutas 
N,  Vlachodimitropoulos  D,  Vassilaros  SD,  Katsantoni  EZ,  Vo-
loudakis-Baltatzis I, Aleporou-Marinou V, Kittas C, Marinos E. Al-
tered expression pattern of integrin v3 correlates with actin cyto-
skeleton in primary cultures of human breast cancer. Cancer Cell Int 
2007; 7: 16-26. 
21.  Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, 
Anderson RL. Tumor-specific expression of v3 integrin promotes 
spontaneous metastasis of breast cancer to bone. Breast Cancer Res 
2006; 8: R20. 
22.  Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre 
F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clézardin P. In-
tegrin v3 expression confers on tumor cells a greater propensity to 
metastasize to bone. FASEB J 2002; 16: 1266–1268. 
23.  Zitzmann  S,  Ehemann  V,  Schwab  M.  Arginine-Glycine-Aspartic 
acid (RGD)-peptide binds to both tumor and tumor endothelial cells 
in vivo. Cancer Res 2002; 62: 5139–5143.  
24.  Liu S. Radiolabeled cyclic RGD peptides as integrin v3-targeted 
radiotracers: maximizing binding affinity via bivalency. Bioconjug 
Chem 2009; 20: 2199–2213.  
25.  Zhou Y, Chakraborty S, and Liu S. Radiolabeled cyclic RGD pep-
tides as radiotracers for imaging tumors and thrombosis by SPECT. 
Theranostics, 2011; 1: 58-82.  
26.  Liu Z, Fan Wang F, Chen X. Integrin targeted delivery of radio-
therapeutics. Theranostics, 2011; 1: 201-210 
27.  Cai W, Chen X. Multimodality molecular imaging of tumor angio-
genesis. Nucl Med 2008; 49: 113S–128S. 
28.  Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, 
Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. 
Noninvasive visualization of the activiated v3 integrin in cancer 
patients by positron emission tomography and [18F]Galacto-RGD. 
PLoS Med 2005; 2: e70.  
29.  Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, 
Wester HJ, Harbeck N, Schwaiger M. Patterns of v3 expression in 
primary  and  metastatic  human  breast  cancer  as  shown  by 
18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255–259.  
30.  Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks 
TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser 
M, Turton D, Al-Nahhas A, Aboagye EO. Phase I trial of the posi-
tron-emitting  Arg-Gly-Asp  (RGD)  peptide  radioligand 
18F-AH111585  in  breast  cancer  patients.  J  Nucl  Med  2008;  49: 
879–886.  
31.  Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, 
Fangberget A, Tangerud A, Tobin D. Integrin receptor imaging of 
breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. 
J Nucl Med 2006; 47: 1434–1439.  Theranostics 2012, 2(6) 
 
http://www.thno.org 
588 
32.  Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, Liu Z, Wang F, Chen X, 
Liu S. Improving tumor targeting capability and pharmacokinetics 
of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 
2009; 6: 231–245.  
33.  Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, Li F, Liu S, Wang F. Blood 
clearance  kinetics,  biodistribution  and  radiation  dosimetry  of  a 
kit-formulated integrin v3-selective radiotracer  99mTc-3PRGD2 in 
non-human primates. Mol Imaging Biol 2010; 13: 730–736. 
34.  Ma Q, Ji B, Jia B, Gao S, Ji T, Wang X, Han Z, Zhao G. Differential 
diagnosis  of  solitary  pulmonary  nodules  using  99mTc-3P4-RGD2 
scintigraphy. Eur J Nucl Med Mol Imaging 2011; 38: 2145-2152. 
35.  Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H, Liu S. 99mTc-labeled 
cyclic RGD peptides for noninvasive monitoring of tumor integrin 
v3 expression. Mol Imaging 2011; 10: 386–397. 
36.  Shao G, Zhou Y, Wang F, Liu S. Monitoring glioma growth and 
tumor necrosis with u-SPECT-II/CT by targeting integrin αvβ3. Mol 
Imaging 2012; accepted. 
37.  Zetter  BR.  Angiogenesis  and  tumor  metastasis.  Annu  Rev  Med 
1998; 49: 407–424. 
38.  Gay LJ, Felding-Habermann B. Contribution of platelets to tumor 
metastasis. Nat Rev Cancer 2011; 11: 123–134. 
39.  Jain RK. Determinants of tumor blood flow: a review. Cancer Res 
1988; 48: 2641–2658.  
40.  Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris 
A, Watson PH. Necrosis and hypoxia in invasive breast carcinoma. 
Breast Cancer Res Treat 2003; 81: 61–69. 
41.  Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. 
The prognostic value of histological tumor necrosis in solid organ 
malignant  disease:  a  systematic  review.  Future  Oncol  2011;  7: 
1223–1235. 